A $604 million takeover agreement has created a significant opportunity for Mayne Pharma Group Limited (ASX: MYX) shareholders, with Hungarian pharmaceutical group Gedeon Richter offering $6.40 per share in cash.
The proposal represents a 99.4% premium to Mayne Pharma's closing share price on 16 November 2026, highlighting the strategic value of its pharmaceutical portfolio and established US operations.
After a challenging period of acquisition negotiations and operational restructuring, the agreement could mark a decisive turning point for the Australian pharmaceutical company.
Key Numbers Behind the Acquisition
- $604 million: Approximate equity value of the proposed acquisition, including assumed convertible note conversion and equity incentives.
- $6.40 per share: Cash consideration, representing a 99.4% premium to the 16 November 2026 closing price of $3.21.
- 22.14%: Combined shareholding of three major shareholders intending to support the transaction, subject to no superior proposal.
- $95.7 million: Unaudited revenue for the September 2026 quarter.
- 84,000 prescriptions: DistributeRx quarterly volume, representing 120% year-on-year growth.
A Major Step Towards Unlocking Shareholder Value
Under the scheme implementation deed announced on 17 November 2026, Gedeon Richter has agreed to acquire 100% of Mayne Pharma through a scheme of arrangement.
The agreement follows the termination of an earlier $7.40-per-share acquisition proposal from Cosette Pharmaceuticals and subsequent legal proceedings.
The new transaction provides a clear pathway towards delivering substantial cash consideration to shareholders.
Importantly, Richter intends to fund the acquisition entirely through existing cash resources, removing the uncertainty associated with external financing arrangements.
Mayne Pharma's board has unanimously recommended the proposal, subject to an independent expert concluding that the scheme is in shareholders' best interests and no superior proposal emerging.
Completion remains subject to regulatory, shareholder and court approvals, alongside the company's planned international business divestment.
What Stands Out to Us
The acquisition highlights the strategic importance of Mayne Pharma's established US pharmaceutical operations.
Richter already owns the estetrol franchise underlying NEXTSTELLIS, Mayne Pharma's US contraceptive product, creating a strong commercial connection between the businesses.
Bringing Mayne Pharma into Richter's broader pharmaceutical portfolio could strengthen distribution capabilities, expand its presence in women's health and create opportunities for operational efficiencies.
Although September-quarter underlying EBITDA declined 52% to $5.3 million, Mayne Pharma continues to demonstrate encouraging growth across important product categories.
The company also held $67.3 million in cash and marketable securities at 30 September 2026.
We think Richter's willingness to commit approximately $604 million demonstrates the strategic appeal of Mayne Pharma's brands, distribution network and established market position, despite recent earnings pressures.
What Mayne Pharma Is Doing Now
Mayne Pharma continues to advance its operational transformation while preparing for the proposed acquisition.
The company is progressing the $55.5 million sale of its international operations to Evaris Pharma, a transaction designed to simplify its business structure and sharpen its focus on the US market.
Its DistributeRx platform delivered approximately 84,000 prescriptions during the September quarter, representing 120% year-on-year growth.
Meanwhile, NEXTSTELLIS demand cycles increased 27%, while IMVEXXY prescription volumes rose 13%.
Mayne Pharma is also preparing to open an expanded automated pharmacy facility in Lexington, Kentucky, in early 2027.
Together, these developments highlight the company's ongoing efforts to strengthen its distribution capabilities, improve operational efficiency and expand its commercial reach.
Insight: Could Richter Unlock Greater Value From Mayne Pharma?
We think the proposed acquisition represents a positive development that recognises the strategic value of Mayne Pharma's pharmaceutical portfolio beyond its recent earnings performance. Richter's established relationship with the company, combined with its international pharmaceutical operations, creates a credible opportunity to improve commercial efficiency and strengthen the US women's health business. While declining EBITDA demonstrates that operational challenges remain, growing prescription volumes provide encouraging evidence of underlying demand. The fully funded proposal strengthens transaction certainty, although regulatory approvals and completion conditions remain important considerations.
What Happens Next?
Mayne Pharma expects its first court hearing in December 2026, followed by a shareholder meeting in late January 2027.
Implementation is targeted for mid-to-late March 2027, subject to the necessary approvals and satisfaction of transaction conditions.
The proposed $55.5 million international business divestment remains an important milestone, alongside Foreign Investment Review Board approval and US antitrust clearance.
The independent expert's report will also help shareholders assess the proposed $6.40-per-share consideration.
With a substantial takeover premium, existing strategic relationships and a fully funded acquisition proposal, Mayne Pharma has secured a significant opportunity to deliver shareholder value.
Successful completion would bring its latest corporate transformation to a conclusion while positioning its established pharmaceutical brands within Richter's larger international business.